A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

Phase 0 Recruiting 22 enrolled Vivacta Biotechnology (Shanghai) Co., Ltd. RenJi Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy and cellular pharmacokinetics of GT801 injection in patients with moderate to severe refractory autoimmune diseases.

Timeline

Start: 2026-05-25
Primary completion: 2031-12-30
Completion: 2031-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GT801	Unknown	—	—

Indications

No indication recorded.